TIE2 (P883A)
Sign in to save this workspaceTEK · Variant type: point · HGVS: p.P883A
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Ponatinib | 99.0% | 1.0% | 78.23 |
| 2 | Ripretinib | 97.9% | 2.1% | 92.95 |
| 3 | Crizotinib | 96.9% | 3.1% | 91.39 |
| 4 | Cabozantinib | 96.5% | 3.5% | 92.73 |
| 5 | Tivozanib | 95.3% | 4.7% | 92.42 |
| 6 | Brigatinib | 93.8% | 6.2% | 82.96 |
| 7 | Axitinib | 92.7% | 7.3% | 93.23 |
| 8 | Repotrectinib | 92.4% | 7.6% | 84.21 |
| 9 | Nintedanib | 91.1% | 8.9% | 90.23 |
| 10 | Neratinib | 88.9% | 11.1% | 93.18 |
| 11 | Infigratinib | 78.2% | 21.8% | 98.24 |
| 12 | Nilotinib | 73.9% | 26.1% | 96.49 |
| 13 | Dabrafenib | 73.3% | 26.7% | 94.74 |
| 14 | Vandetanib | 72.5% | 27.5% | 95.74 |
| 15 | Erdafitinib | 63.4% | 36.6% | 95.71 |
| 16 | Defactinib | 61.4% | 38.6% | 92.68 |
| 17 | Entrectinib | 61.1% | 38.9% | 93.69 |
| 18 | Bosutinib | 60.1% | 39.9% | 87.22 |
| 19 | Pemigatinib | 54.7% | 45.3% | 98.23 |
| 20 | Lenvatinib | 54.3% | 45.7% | 97.74 |
| 21 | Fostamatinib | 52.6% | 47.4% | 96.74 |
| 22 | Pacritinib | 47.0% | 53.0% | 88.64 |
| 23 | Canertinib | 44.1% | 55.9% | 96.49 |
| 24 | Ibrutinib | 39.9% | 60.1% | 94.74 |
| 25 | Apatinib | 38.7% | 61.3% | 97.73 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Ponatinib | 99.0% | — | — |
| Ripretinib | 97.9% | — | — |
| Crizotinib | 96.9% | — | — |
| Cabozantinib | 96.5% | — | — |
| Tivozanib | 95.3% | — | — |
| Brigatinib | 93.8% | — | — |
| Axitinib | 92.7% | — | — |
| Repotrectinib | 92.4% | — | — |
| Nintedanib | 91.1% | — | — |
| Neratinib | 88.9% | — | — |
| Infigratinib | 78.2% | — | — |
| Nilotinib | 73.9% | — | — |
| Dabrafenib | 73.3% | — | — |
| Vandetanib | 72.5% | — | — |
| Erdafitinib | 63.4% | — | — |
| Defactinib | 61.4% | — | — |
| Entrectinib | 61.1% | — | — |
| Bosutinib | 60.1% | — | — |
| Pemigatinib | 54.7% | — | — |
| Lenvatinib | 54.3% | — | — |
| Fostamatinib | 52.6% | — | — |
| Pacritinib | 47.0% | — | — |
| Canertinib | 44.1% | — | — |
| Ibrutinib | 39.9% | — | — |
| Apatinib | 38.7% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.0ms